These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16101463)

  • 1. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets.
    Vandevoorde S; Lambert DM
    Curr Pharm Des; 2005; 11(20):2647-68. PubMed ID: 16101463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
    Minkkilä A; Saario S; Nevalainen T
    Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
    Vandevoorde S
    Curr Top Med Chem; 2008; 8(3):247-67. PubMed ID: 18289091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation.
    Alvarez-Jaimes LJ; Palmer JA
    Curr Pharm Biotechnol; 2011 Oct; 12(10):1644-59. PubMed ID: 21466449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol.
    Ho WS; Randall MD
    Br J Pharmacol; 2007 Mar; 150(5):641-51. PubMed ID: 17245358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis.
    Feledziak M; Lambert DM; Marchand-Brynaert J; Muccioli GG
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):49-70. PubMed ID: 22280341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
    Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
    Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into endocannabinoid degradation and its therapeutic potential.
    Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M
    Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.
    Saario SM; Laitinen JT
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):287-93. PubMed ID: 17910610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoid hydrolases.
    Ueda N
    Prostaglandins Other Lipid Mediat; 2002 Aug; 68-69():521-34. PubMed ID: 12432941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
    Bajaj S; Jain S; Vyas P; Bawa S; Vohora D
    Brain Res Bull; 2021 Sep; 174():305-322. PubMed ID: 34217798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel natural and synthetic ligands of the endocannabinoid system.
    Hanus LO; Mechoulam R
    Curr Med Chem; 2010; 17(14):1341-59. PubMed ID: 20166928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid amide hydrolase inhibitors--progress and potential.
    Khanna IK; Alexander CW
    CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):545-58. PubMed ID: 21631410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of alpha/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons.
    Marrs WR; Horne EA; Ortega-Gutierrez S; Cisneros JA; Xu C; Lin YH; Muccioli GG; Lopez-Rodriguez ML; Stella N
    J Biol Chem; 2011 Aug; 286(33):28723-28728. PubMed ID: 21665953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulators of endocannabinoid enzymic hydrolysis and membrane transport.
    Ho WS; Hillard CJ
    Handb Exp Pharmacol; 2005; (168):187-207. PubMed ID: 16596775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology of the enzymes that degrade endocannabinoids.
    Puffenbarger RA
    Curr Drug Targets CNS Neurol Disord; 2005 Dec; 4(6):625-31. PubMed ID: 16375680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
    Vandevoorde S; Fowler CJ
    Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.
    Fowler CJ
    Handb Exp Pharmacol; 2015; 231():95-128. PubMed ID: 26408159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
    Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
    J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.
    Ghafouri N; Tiger G; Razdan RK; Mahadevan A; Pertwee RG; Martin BR; Fowler CJ
    Br J Pharmacol; 2004 Nov; 143(6):774-84. PubMed ID: 15492019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.